[
  {
    "ts": "2025-10-27T20:00:00+00:00",
    "headline": "Vertex to Participate in the UBS Global Healthcare Conference on November 11",
    "summary": "BOSTON, October 27, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET.",
    "url": "https://finance.yahoo.com/news/vertex-participate-ubs-global-healthcare-200000178.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "2db9ee6b-1c1a-37b7-b304-380bb56b581a",
      "content": {
        "id": "2db9ee6b-1c1a-37b7-b304-380bb56b581a",
        "contentType": "STORY",
        "title": "Vertex to Participate in the UBS Global Healthcare Conference on November 11",
        "description": "",
        "summary": "BOSTON, October 27, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET.",
        "pubDate": "2025-10-27T20:00:00Z",
        "displayTime": "2025-10-27T20:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/888f9460eaf4f34a43b53d93dc725d5b",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZDwKtm8zwCFi_ylPW.4uZQ--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/888f9460eaf4f34a43b53d93dc725d5b.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LinnHv6YjXxmCVRRUAhUTw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/888f9460eaf4f34a43b53d93dc725d5b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-participate-ubs-global-healthcare-200000178.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-participate-ubs-global-healthcare-200000178.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T16:03:00+00:00",
    "headline": "Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial",
    "summary": "The gene-editing biotech  Intellia Therapeutics  said Monday it had paused two trials of one of its lead experimental treatments after a patient was hospitalized due to liver problems.  On an investor call, Intellia’s CEO, John Leonard, said that the company had learned Friday that a patient in a trial of the company’s experimental gene-editing treatment for a heart disease called ATTR-cardiomyopathy had been hospitalized after reporting stomach pain.",
    "url": "https://www.barrons.com/articles/intellia-therapeutics-stock-drug-safety-0e7cb5f2?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "332f65b5-276a-36d5-a7f4-eed6a455313f",
      "content": {
        "id": "332f65b5-276a-36d5-a7f4-eed6a455313f",
        "contentType": "STORY",
        "title": "Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial",
        "description": "",
        "summary": "The gene-editing biotech  Intellia Therapeutics  said Monday it had paused two trials of one of its lead experimental treatments after a patient was hospitalized due to liver problems.  On an investor call, Intellia’s CEO, John Leonard, said that the company had learned Friday that a patient in a trial of the company’s experimental gene-editing treatment for a heart disease called ATTR-cardiomyopathy had been hospitalized after reporting stomach pain.",
        "pubDate": "2025-10-27T16:03:00Z",
        "displayTime": "2025-10-27T16:03:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/332f65b5-276a-36d5-a7f4-eed6a455313f/intellia-therapeutics-stock.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/87f78ce7754242d909c20bfd739ab5df",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KONq7EdcocUqYA0Wc9RLyQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/87f78ce7754242d909c20bfd739ab5df.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ycdcveKSxwZFDacfy0QqSQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/87f78ce7754242d909c20bfd739ab5df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/intellia-therapeutics-stock-drug-safety-0e7cb5f2?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "NTLA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T14:00:19+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?",
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-earnings-expected-140019036.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b3be0096-7032-3143-8f23-b6102d5339a0",
      "content": {
        "id": "b3be0096-7032-3143-8f23-b6102d5339a0",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?",
        "description": "",
        "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2025-10-27T14:00:19Z",
        "displayTime": "2025-10-27T14:00:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ucluz4bedY7Dxd_XS4xCHQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Asv6z7WU__xaJFJkAJhxZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-earnings-expected-140019036.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-earnings-expected-140019036.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T13:00:03+00:00",
    "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finance.yahoo.com/news/strong-medical-stocks-slated-positive-130003908.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9ae7a381-42c0-3e91-af8d-9b230eba5da4",
      "content": {
        "id": "9ae7a381-42c0-3e91-af8d-9b230eba5da4",
        "contentType": "STORY",
        "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
        "description": "",
        "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
        "pubDate": "2025-10-27T13:00:03Z",
        "displayTime": "2025-10-27T13:00:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be",
          "originalWidth": 900,
          "originalHeight": 594,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jcpSnlhnuuUas5U.67zBPQ--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be.cf.webp",
              "width": 900,
              "height": 594,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gk1JxpBvTuD8ecx2ZnLlEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strong-medical-stocks-slated-positive-130003908.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strong-medical-stocks-slated-positive-130003908.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T09:43:00+00:00",
    "headline": "Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030",
    "summary": "Vertex appears to be by far the better buy right now.",
    "url": "https://www.fool.com/investing/2025/10/27/prediction-vertex-pharmaceuticals-will-be-worth-mo/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e12ba376-46bd-3a5b-a443-cee854c16bd1",
      "content": {
        "id": "e12ba376-46bd-3a5b-a443-cee854c16bd1",
        "contentType": "STORY",
        "title": "Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030",
        "description": "",
        "summary": "Vertex appears to be by far the better buy right now.",
        "pubDate": "2025-10-27T09:43:00Z",
        "displayTime": "2025-10-27T09:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/46d6eeb91d90cf50132b34d2a146bc3a",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor holding patient's hands.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NoBMo9Ua30jTr0d46Ed6Bw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/46d6eeb91d90cf50132b34d2a146bc3a.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sS7Pr3zhfR1lcGWgQa3Tyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/46d6eeb91d90cf50132b34d2a146bc3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/27/prediction-vertex-pharmaceuticals-will-be-worth-mo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-vertex-pharmaceuticals-worth-more-094300795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]